{"id":837579,"date":"2025-04-15T13:06:05","date_gmt":"2025-04-15T17:06:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/"},"modified":"2025-04-15T13:06:05","modified_gmt":"2025-04-15T17:06:05","slug":"the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/","title":{"rendered":"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, April  15, 2025  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>Actinium Pharmaceuticals, Inc. (NYSE: ATNM).<\/strong><\/p>\n<p>Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WQSfHcfPkBhHnwXoU2HVurtr8tvYdDAvUnJYcsOvoVGACiESlX068h-17OCoGzVqqE32GoyNGPp2rAI3Dv-U4ni0hZf7bRa5zkBtNYuzQFF3sWjWbsQa6YWhR0d2MCA9CO55SkGOuOJW9Gc5pBgGyiK5idqu9AFUNs5SgbDvgI5BlUSN0fJh5nMGERlc0KFG1XS-bFiCMymOKjh8DDrxplRfWeQ4qV3AA5SkuXBoMH2FbEXn6jOLuyPS-kYdkcBEFFw7wvUf_sJND01zaJY_5lAm8pj8idCw7fT_OwlvQwo=\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/actinium-loss-submission-form\/?id=142482&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>October 31, 2022 to August 2, 2024<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the Company\u2019s data from the Phase 3 Sierra trial was unlikely to satisfy the FDA\u2019s guidelines for the acceptance and approval of the Company\u2019s targeted radiotherapy, Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial\u2019s poor OS data were unlikely to satisfy the FDA\u2019s guidelines for the acceptance and approval of the Company\u2019s Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n<p>\n        <strong>DEADLINE: May 27, 2025<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WQSfHcfPkBhHnwXoU2HVurtr8tvYdDAvUnJYcsOvoVGACiESlX068h-17OCoGzVqqE32GoyNGPp2rAI3Dv-U4ni0hZf7bRa5zkBtNYuzQFF3sWjWbsQa6YWhR0d2MCA9r-qiqWJtM7iVOwl9IEdN7xvdrozB2ZUinloZ82jaINh61_v7xIMrAWWCsbR2qGmQHvI17hqZNuDsVo2sPr5bREUZBACbGO6rgytW5VQRR00o1mlzcviUXsB5_2rpyPRsqTibpghaeRXp7iEctMy8l2g4WoG1lFOT2inlKBUSwSQ=\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/actinium-loss-submission-form\/?id=142482&amp;from=3<\/a><\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of ATNM during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 27, 2025. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zlDncmS5ij4Txs8YoEtlzpn7D7IwpzNFVtop3U7IXY3Hn8ukWhuIrdRHODpiu_xRcOtTUxpFrDPX-z9AW49x5qfAMHCCuNx16V3ES892pXmVgRiulb52w08jjKH79zjq\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a>\u00a0<br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjRhMTA4N2UtNTA0MC00NmY4LTk5MjgtNjVkNTAxY2RiYTFhLTEyNzA0NjctMjAyNS0wNC0xNS1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/actinium-loss-submission-form\/?id=142482&amp;from=3 CLASS PERIOD: October 31, 2022 to August 2, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the Company\u2019s data from the Phase 3 Sierra trial was unlikely to satisfy the FDA\u2019s guidelines for the acceptance and approval of the Company\u2019s targeted radiotherapy, Iomab-B &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837579","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/actinium-loss-submission-form\/?id=142482&amp;from=3 CLASS PERIOD: October 31, 2022 to August 2, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the Company\u2019s data from the Phase 3 Sierra trial was unlikely to satisfy the FDA\u2019s guidelines for the acceptance and approval of the Company\u2019s targeted radiotherapy, Iomab-B &hellip; Continue reading &quot;The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T17:06:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM\",\"datePublished\":\"2025-04-15T17:06:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/\"},\"wordCount\":463,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/\",\"name\":\"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=\",\"datePublished\":\"2025-04-15T17:06:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/","og_locale":"en_US","og_type":"article","og_title":"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM - Market Newsdesk","og_description":"NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/actinium-loss-submission-form\/?id=142482&amp;from=3 CLASS PERIOD: October 31, 2022 to August 2, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the Company\u2019s data from the Phase 3 Sierra trial was unlikely to satisfy the FDA\u2019s guidelines for the acceptance and approval of the Company\u2019s targeted radiotherapy, Iomab-B &hellip; Continue reading \"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-15T17:06:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM","datePublished":"2025-04-15T17:06:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/"},"wordCount":463,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/","name":"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=","datePublished":"2025-04-15T17:06:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTE1OSM2ODYzMDUwIzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/the-gross-law-firm-notifies-actinium-pharmaceuticals-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-atnm-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"The Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline \u2013 ATNM"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837579"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837579\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}